Breast cancer is a heterogeneous disease comprising multiple molecular subtypes, including estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–positive (HER2+), and triple-negative breast cancer (TNBC), each characterized by distinct biological behaviors and therapeutic vulnerabilities [1,39]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.